March 12, 2026 06:41 am (IST)

Make this your homepage

Health

Supreme Court allows first-ever passive euthanasia for 32-year-old man in coma for 13 years | As Iran-US war disrupts global gas supply, India issues guidelines to manage shortages | LPG crisis hits metros: Commercial cylinder shortage triggers panic as govt prioritises domestic supply | Iran war disrupts LPG supplies, restaurants in major Indian cities edge towards shutdown | ‘How dare you question judicial officers?’: SC raps Bengal SIR pleas, orders appellate tribunals for voter list appeals | 'Book withdrawn': NCERT apologises for controversial judiciary chapter after Supreme Court ban | Indian stock market surges as Brent crude dips below $100 after Trump’s Iran remarks | Australia grants asylum to five Iranian women footballers after anthem protest; Albanese says ‘they are safe here’ | Trump administration labels Afghanistan ‘state sponsor of wrongful detention’ | Trump threatens Iran with ‘20 times harder’ strike if oil flow through Strait of Hormuz is disrupted

COVID Naval Vaccine

Wikipedia Commons

Covaxin maker's nasal Covid vaccine cleared for emergency use, announces Mansukh Mandaviya

India Blooms News Service | @indiablooms | Sep 06, 2022, at 10:29 pm

#Covaxin #CovaxinNavalVaccine #COVID19

New Delhi: Bharat Biotech’s needle-free intranasal vaccine against Covid-19 has gained emergency use approval in India Union health minister Mansukh Mandaviya confirmed on Tuesday.

The Minister said the step will further strengthen India's collective fight against the pandemic.

The vaccine could be delivered through naval route.

This step will further strengthen our collective fight against the pandemic.

India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji's leadership.

With the science-driven approach & Sabka Prayas, we will defeat COVID-19.
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022

"Big Boost to India's Fight Against COVID-19! Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation," the Minister tweeted.

Big Boost to India's Fight Against COVID-19!

Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022

"This step will further strengthen our collective fight against the pandemic. India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji's leadership. With the science-driven approach & Sabka Prayas, we will defeat COVID-19," he said.

India reported 4,417 new Covid-19 cases while the toll went up by 23 in the last 24 hours, the Union Health Ministry said Tuesday.

In the same span of time, 6,032 Covid-19 patients have recovered from across the country.

The active cases, which now stand at 52,336, forms 0.12% of the total number of infections.

The recovery rate now stands at 98.69%.

Under the national vaccination drive, 213.72 crore anti-Covid vaccine doses have been administered in the country.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.